Viewing Expert Jerome Hass | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Viewing Expert

Jerome Hass , Portfolio Manager

Lightwater Partners

Address
120 Adelaide Street West, Suite 2400
Toronto, On
M5H 1T1

Contact Info
Telephone: +1 (416) 504-9767
Email:
Website: http://www.lightwaterpartners.com/home.html

Bio:

Lightwater Partners is a Toronto-based  alternative asset manager.  Lightwater  focuses on mid-cap Canadian stocks and long / short strategies.  It manages two funds, the Lightwater Long Short Fund and the Nimble Fund.  These two funds returned 46% and 53% respectively in 2013 (returns net of all fees and expenses).  Lightwater was established in 2007 and it was one of the small number of Canadian managers who earned a positive return in 2008.


Date Signal Chart Symbol Company Opinion Price
2017-10-04 COMMENT Must be logged in to use chart A Commentary A Comment -- General Comments From an Expert

Marijuana. Doesn’t believe any of the current players will ever make money in the marijuana business. In Canada, we have to heat greenhouses in the winter and cool them in the summer, when compared to someone in a more temperate climate, who doesn’t have any of those costs. In Ontario, they are going to be marketed through an LCBO equivalent which is going to be a high cost structure. Doesn’t think they will be able to put the black-market out of business.


Price:
$0.020
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
No
2017-10-04 WEAK BUY Must be logged in to use chart AC-T Air Canada

Plugged his nose and bought this a year or 2 ago, because he has Short positions in the airline sector so is using Air Canada for hedging purposes. It had a phenomenal run this year. He would be cautious about adding to it. It should trade closer to its American peers, and is trading at a discount, so he does see some upside.


Price:
$26.050
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
Yes
2017-10-04 SELL Must be logged in to use chart AD-T Alaris Royalty

Has looked at this over the years, and never thought they charged enough for their product. They hold about a dozen investments and collect a royalty off of that. He would be very cautious on this. If you own, you might consider taking your money off the table.


Price:
$20.660
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
No
2017-10-04 COMMENT Must be logged in to use chart BIOA-N BioAmber Inc

Produces succinic acid, an intermediate product that can be used in things like plastic, artificial leather, etc. The asset is generally made in Asia and from petroleum products, but they make theirs from industrial sugars, which is generally cheaper than that made from petroleum. They just haven’t executed on anything, so it has been one of the worst investments he has had this year. He questions if they will stay in business.


Price:
$0.471
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
No
2017-10-04 COMMENT Must be logged in to use chart BMO-T Bank of Montreal

Has been Short on this for over 8 years now, through a Pairs trade, being Long on Guardian Capital (GCG-T). When he did this in 2009, Guardian was trading at about a 25% discount just to the value of its BMO shares. Effectively, he was buying BMO $.50 to the dollar. Both stocks have gone up, but Guardian has gone up more and the spread has widened. This is one of the reasons he really likes Pair Trading.


Price:
$96.350
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
Yes
2017-10-04 COMMENT Must be logged in to use chart CBL-T Callidus Capital Corp

He is still very confident in this. In Oct /16 they announced a privatization plan, and hired Goldman Sachs to lead the process. Had set a guidance on privatization by the end of June/17. Shortly before that, they announced privatization had been delayed, so the share price sold off. Management still expects something to occur in the fall, and still remains positive. A very good business. The underlying capacity has actually grown over the last 1-1.5 years, so when they do re-start their lending, the capacity of the company will be something that will be taken into account by potential buyers. When they announced the delay, they also announced they were exploring opportunities with private debt funds, which is something that hadn’t been taken into account. 12% dividend yield is a red flag to investors, but the leverage of the company is 25%-30%, and management feels it should be closer to 70%. They will absolutely use their balance sheet to fund the dividend, and there is no way they will cut the dividend.


Price:
$10.120
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
Yes
2017-10-04 COMMENT Must be logged in to use chart CCL.B-T CCL Industries (B)

This has been a fantastic stock over the last 5 years. Has a $10 or $12 billion market cap, so is not a name that is within his sweet spot.


Price:
$61.830
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
No
2017-10-04 COMMENT Must be logged in to use chart CGX-T Cineplex Inc

Has a Short position. It is so widely held by Canadians, portfolio managers, and virtually every mutual fund. Has always traded in a band of $48 and $52. Their Q2 numbers were way down as a result of a very poor box office. People underestimated the cost of the launch of the new ventures, and it finally broke out of that band and gapped down to around $37. A good company, but trades at twice the valuation of its US peers.


Price:
$39.660
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
Yes
2017-10-04 TOP PICK Must be logged in to use chart CJT-T Cargojet Inc

Has more than 90% market share in Canada in the overnight carrier business. A great play on e-commerce in Canada. E-commerce volumes are going up 50% year-over-year. Dividend yield of 1.6%. (Analysts’ price target is $56.)


Price:
$50.420
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
Yes
2017-10-04 TOP PICK Must be logged in to use chart CRH-T CRH Medical Corp.

Has been looking at this for over 2 years, and met management repeatedly. Was aware of the Short attack circulating this summer, which had some pretty interesting important points to make. When a share price goes from $12 to around $3, his view is that it was fully priced in and there was a big overreaction by the street. They are exclusively based in the US, and have a medical product that is used by gastroenterologists in the clinics, kind of a Trojan horse for them because they have the clinics that are using the medical product, so have a relationship with them. With a number of the clinics, they have effectively bought 50% of the clinic, which allows them to provide the anaesthesia services on behalf of the doctors who work there. A pristine balance sheet. (Analysts’ price target is $5.)


Price:
$3.260
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
Yes
2017-10-04 COMMENT Must be logged in to use chart CXI-T Currency Exchange Intl.

Supplies physical foreign exchange. They’ve diversified into the payments business, which has caused a few headaches for them in the last few years. It is still not in profit mode. There was a lot of excitement last Sept/16, when they got their bank license, and it was thought they would take the Canadian market by storm. The reality is that it has been a tougher slog in the Canadian market. Incumbents were a little more resilient than what had been thought. Q3 had record revenues, but expenses were a little higher than expected. Expenses continue to grow. Sold his holdings this summer, largely on valuations. It is difficult to justify the stock given its outlook for growth and profitability.


Price:
$25.430
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
No
2017-10-04 PAST TOP PICK Must be logged in to use chart DSG-T Descartes

(A Top Pick July/16. Up 44.92%.) Investors like this name because of its predictability. When a quarter starts, because of so much recurring revenues, they already know what 90% of revenue is going to look like. Because of this, they spend the last 90 days of the quarter trying to get the next 10% in. It is always a non-event when they come out with quarters, and portfolio managers love that, and pay up for it. A growth story and a play on global trade and on increasing returns on cross-border traffic. A very good, long term story.


Price:
$35.160
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
Yes
2017-10-04 PAST TOP PICK Must be logged in to use chart ECI-T EnerCare Inc

(A Top Pick July/16. Up 27.57%.) He still thinks the street is not giving them enough credit for the sub-metering business. There is a fair amount of excitement about an acquisition they did in the US and Canada, called Service Experts, which is more on the service side for HVAC business.


Price:
$20.840
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
Yes
2017-10-04 PAST TOP PICK Must be logged in to use chart EFL-T Electrovaya Inc.

(A Top Pick July/16.) *Short* Up 74.69%. A lithium ion battery company. Made an acquisition in Germany, and the head of the company had to pay $250,000 to OSC over a disclosure that the OSC felt was a bit rosy. His analysis suggests this is worth significantly less then the current share price.


Price:
$1.050
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
No
2017-10-04 COMMENT Must be logged in to use chart GMP-T GMP Capital Trust Inc

There has been a lot of negativity weighing on the common shares, and conversely, Canaccord (CF-T) seems to have done a lot better over the last 1.5 years, so people have often looked at the difference between the 2. Canaccord is more heavily weighted towards cannabis stocks, which have done very well. Also made an acquisition a year ago of First Energy, which hasn’t worked for them. In terms of Preferred B shares, which he owns, it gives a decent yield, and at some point, thinks GMP and its wealth management side could be a potential interest to a 3rd party. He would rather own the Preferred B then the common shares.


Price:
$2.600
Subject:
CANADIAN MIDCAP
Bias:
UNKNOWN
Owned:
Yes
Showing 1 to 15 of 610 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.